Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 345,630
  • Shares Outstanding, K 243,260
  • Annual Sales, $ 38,330 K
  • Annual Income, $ -107,980 K
  • 36-Month Beta -0.68
  • Price/Sales 7.46
  • Price/Book 84.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.35 +1.48%
on 01/18/17
1.56 -12.18%
on 01/05/17
-0.09 (-6.16%)
since 12/16/16
3-Month
1.35 +1.48%
on 01/18/17
1.67 -17.96%
on 11/15/16
-0.16 (-10.46%)
since 10/18/16
52-Week
1.32 +3.79%
on 02/03/16
2.16 -36.57%
on 06/09/16
-0.28 (-16.97%)
since 01/15/16

Most Recent Stories

More News
VIVUS Licenses Rights to PAH Drugs from Selten Pharma

VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.

Puma (PBYI) Expands Study Cohort for Lead Candidate PB272

Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating...

Vertex Pharma Issues Disappointing 2017 Orkambi Outlook

Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference...

Genocea Stock Up on Positive Genital Herpes Infections Data

Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections....

Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing...

Arena, Eisai Modify Marketing & Supply Agreement for Belviq

Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.

Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III

Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.

Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine...

Bristol-Myers Extends Deal with Five Prime Therapeutics

Bristol-Myers (BMY) has exercised its option to extend the research term of the existing collaboration agreement with Five Prime Therapeutics (FPRX).

Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained

Alexion (ALXN) has finally announced the filing of its Form 10-Q with the SEC for the period ended Sep 30, 2016 and retained its outlook for 2016.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Support & Resistance

2nd Resistance Point 1.42
1st Resistance Point 1.40
Last Price 1.37
1st Support Level 1.35
2nd Support Level 1.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.